The SEMRCNN model is proposed for autonomously extracting prostate cancer locations from regions of multiparametric magnetic resonance imaging (MP-MRI). Feature maps are explored in order to provide fine segmentation based on the candidate regions. Two parallel convolutional networks retrieve these maps of apparent diffusion coefficient (ADC) and T2W images, which are then integrated to use the complimentary information in MP-MRI. By utilizing extrusion and excitation blocks, it is feasible to automatically increase the number of relevant features in the fusion feature map. The aim of this study is to study the current scenario of the SE Mask-RCNN and deep convolutional network segmentation model that can automatically identify prostate cancer in the MP-MRI prostatic region. Experiments are conducted using 140 instances. SEMRCNN segmentation of prostate cancer lesions has a Dice coefficient of 0.654, a sensitivity of 0.695, a specificity of 0.970, and a positive predictive value of 0.685. SEMRCNN outperforms other models like as V net, Resnet50-U-net, Mask-RCNN, and U network model for prostate cancer MP-MRI segmentation. This approach accomplishes fine segmentation of lesions by recognizing and finding potential locations of prostate cancer lesions, eliminating interference from surrounding areas, and improving the learning of the lesions’ features.

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

Alzheimer’s disease is incurable at the moment. If it can be appropriately diagnosed, the correct treatment can postpone the patient’s illness. To aid in the diagnosis of Alzheimer’s disease and to minimize the time and expense associated with manual diagnosis, a machine learning technique is employed, and a transfer learning method based on 3D MRI data is proposed. Machine learning algorithms can dramatically reduce the time and effort required for human treatment of Alzheimer’s disease. This approach extracts bottleneck features from the M-Net migration network and then adds a top layer to supervised training to further decrease the dimensionality and delete portions. As a consequence, the transfer network presented in this study has several advantages in terms of computational efficiency and training time savings when used as a machine learning approach for AD-assisted diagnosis. Finally, the properties of all subject slices are combined and trained in the classification layer, completing the categorization of Alzheimer’s disease symptoms and standard control. The results show that this strategy has a 1.5 percentage point better classification accuracy than the one that relies exclusively on VGG16 to extract bottleneck features. This strategy could cut the time it takes for the network to learn and improve its ability to classify things. The experiment shows that the method works by using data from OASIS. A typical transfer learning network’s classification accuracy is about 8% better with this method than with a typical network, and it takes about 1/60 of the time with this method.

The retinoblastoma gene (RB1), which is located on chromosome 13q14.2, is mutated in retinoblastoma (RB), the most common malignant intraocular tumor in children. About 8000 new cases of retinoblastoma are diagnosed globally each year, accounting for approximately 1 in 17,000 live births. RB is prototypically considered hereditary by nature as thirty to forty percent of cases have autosomal dominant inheritance, and the remaining sixty to seventy percent have non-inherited sporadic inheritance. RB is the most treatable juvenile malignancy, with a high percentage of survival; nevertheless, advanced tumors restrict the amount of globe salvage and are frequently linked to high-risk histological characteristics that indicate spread. Investigating the disease’s molecular causes has also helped to understand its subsequent processes, which has resulted in the identification of biomarkers and relevant targeted treatments. Additionally, advancements in molecular biology techniques facilitated the creation of effective strategies for early disease detection, genetic counseling, and prevention. In the present review, we discuss the risk factors, epidemiology, pathology, and therapeutic approaches for retinoblastoma. We specifically focus on the genetic and molecular characteristics of retinoblastoma, including mutations that cause key signaling pathways involved in the DNA repair, cellular plasticity, and cell proliferation to become dysregulated.

All cells and intracellular components are remodeled and recycled in order to replace the old and damaged cells. Autophagy is a process by which damaged and unwanted cells are degraded in the lysosomes. There are three different types of autophagy, and these include macroautophagy, microautophagy and chaperonemediated autophagy. Autophagy has an effect on adaptive and innate immunity, suppression of any tumour and the elimination of various microbial pathogens. The process of autophagy has both positive and negative effects and this pertains to any specific disease or its stage of progression. Autophagy involves various processes which are controlled by various signaling pathways, such as Jun N-terminal kinase, GSK3, ERK1, Leucine-rich repeat kinase 2, and PTEN-induced putative kinase 1 and parkin RBR E3. Protein kinases are also important for the regulation of autophagy as they regulate the process of autophagy either by activation or inhibition. In the present review, we discuss the kinase catalyzed phosphorylated reactions, the kinase inhibitors, types of protein kinase inhibitors and their binding properties to protein kinase domains, the structures of active and inactive kinases, and the hydrophobic spine structures in active and inactive protein kinase domains. The intervention of autophagy by targeting specific kinases may form the mainstay of treatment of many diseases and lead the road to future drug discovery.

Diabetic neuropathy (DN) is a common and debilitating complication of diabetes mellitus, often presenting with chronic pain and sensory or motor deficits. Current treatment options provide only partial symptomatic relief and are frequently associated with adverse effects, underscoring the need for more effective and targeted approaches. Microneedle (MN) technology has emerged as a minimally invasive, highly efficient, transdermal-delivery strategy offering increased drug absorption, sustained drug release, and patient compliance. Different designs of MN, such as solid, coated, dissolving, and hydrogel-based, are available and provide specific strategies in DN management. The patient-specific and solid microneedles, like the lipid-cast microneedles functionalized with the lidocaine and dexamethasone, have demonstrated the possibility to provide long-term pain relief. Emulsion formulations of microneedles made of hydrogel loaded with nerve growth factor show potential in enhancing nerve repair. Biodegradable polymers such as polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP) can be dosed well. Still, more advanced materials, such as polylactide (PLA) and polycaprolactone (PCL), need to be engineered for scalable and cost-efficient production. It has its main obstacles that include drug stability and production, mass culturing, and complicated regulatory processes. The combination of MN platforms, nanomedicine and advanced delivery systems could provide synergistic therapeutic effects that could be the next step towards personalised, effective, and endurable DN treatment. This review identifies new developments, limitations, and areas to explore in terms of using microneedle technology as a method of targeted drug delivery for diabetic neuropathy.